Fig. 2
Survival of VC patients stratified by podoplanin-expression in cancer cells and CAFs. Although within our study cohort overall survival was initially neither related to podoplanin (podoplanin positive vs. podoplanin negative tumors) expression (A) nor the amount of podoplanin positive CAFs (B), a subsequent subgroup analysis determined the prognostic potential of podoplanin positive HPV-associated tumors (Log-rank (Mantel-Cox) test; p = 0.0399, x2 = 4.223; (C). Interestingly, such an effect could not be observed in patients with HPV-independent tumorigenesis (D).
